Loading page…
A diagnostics company turned laboratory capacity into a high-volume COVID testing service during an extraordinary demand window.
40,000 PCR tests/day at peak · 28M tests total
Prenetics built operational capacity around a sudden public need, then cut fast when that demand disappeared.
Fewer bars = easier, cheaper, or faster for an AI-assisted solo builder. Editorial judgments based on the case details.
Danny Yeung describes Prenetics as a life sciences and DNA testing company founded in 2014. COVID created a sudden, large testing need, and the company moved quickly to launch an at-home PCR kit in a little over two weeks. Yeung says the business became Hong Kong's leading PCR provider and also operated in the UK. At peak, the company processed 40,000 tests per day and completed 28 million laboratory PCR tests over roughly three years. He reports more than $700 million in revenue over that period and says Prenetics listed on Nasdaq in 2022. The interview also describes the sharp reversal after testing demand faded: revenue dropped about 95% from a reported $272 million in 2022, and the company cut roughly 2,000 roles. These are founder statements in an interview, not independently verified records. The story is valuable as a scale reference for regulated, capacity-heavy services responding to temporary demand.
Prenetics did not start COVID testing from zero. It was already a Hong Kong life-sciences and DNA-testing company, founded in 2014 by Danny Yeung after he had built the city’s leading e-commerce business, so it had lab know-how and a founder used to selling online.
The quick-reference card — acquisition channels, replication playbook, risks & traps, and our verdict — is members-only.
Join the Unicorn Club — $5/moCancel anytime, in one clickPaste into Claude Code / Codex and get a working version of this product end-to-end.
Two production-grade prompts per idea — a full build spec and an SEO growth plan — plus 10 tailored build specs a week. Members only.
Join the Unicorn Club — $5/moCancel anytime, in one clickEvery claim traces back to a listed source — open any of them and check the number yourself. The exact words are quoted below, with a timestamp that jumps to the second each figure is said.
“This is laboratory PCR test those three years. We did 700 million plus revenue.”
2:44 · hear it in the videoData credibility: My First Million interview with founder Danny Yeung. The $700M+ revenue over three years, $272M in 2022, 40,000 tests a day at peak, 28 million tests in total, the $100 kit price and the 2,000 job cuts are his own statements. Prenetics is Nasdaq-listed, so revenue can be checked in its filings, but none are shown or cited in the interview.
The first COVID revenue came from individuals buying the $100 home kit, paid up front before any lab work was done. Hospitals even called Yeung to ask why the kits were so cheap.
Prenetics’ loop ran on accuracy. Within six months, 14 or 15 laboratories were doing COVID testing in Hong Kong, but Yeung says Prenetics, the first company the government contracted for mass community testing, was the only provider that never had a public problem with false positives or false negatives.
For Prenetics the hard stretch came after the boom, not before it. When testing demand vanished, revenue fell about 95% from $272 million in 2022, and the market value went from a billion-dollar valuation to roughly $50 million within 18 months.
The service combined at-home sample collection with laboratory PCR processing and result delivery. That model shifted the customer experience away from requiring every person to visit a hospital while retaining centralized lab analysis. During the period described, the company also served large-scale public programs, including testing for restaurant workers and airport arrivals in Hong Kong. The operation therefore joined consumer logistics, laboratory throughput, data handling, and institutional contracting. For a founder studying the model, the core product was not simply a test kit: it was a reliable chain from sample distribution through collection, processing, quality control, and communication of results. Each handoff had to work under volume pressure. The founder says the company avoided the false-positive and false-negative incidents that hit other providers; that is his claim, not an audited record. This is a regulated healthcare operation with substantial requirements for labs, staffing, quality systems, and public trust.
Revenue came from paid testing services and institutional testing programs. Yeung says home PCR tests were sold for $100 while hospitals charged $300–$400 for a test at the time. Later, a Hong Kong government program asked the company to test 300,000 restaurant workers across 18,000 restaurants within three weeks. The founder reports more than $700 million in revenue across three years and separately mentions $272 million revenue in 2022 before the post-pandemic contraction. These figures are reported by the founder and should not be treated as audited here. The economics depended on price, lab utilization, supply access, staffing, logistics, and the ability to win large contracts. This was a rare period when demand and public policy could support extraordinary throughput. A new operator should not assume those prices, margins, or volumes can be reproduced in an ordinary diagnostics market.
The operating stack was physical and regulated: laboratory equipment, qualified staff, sample logistics, test-kit supply, data systems, and quality assurance. Yeung describes scaling from roughly 100–200 tests per day to 10,000 daily tests, with logistics, hiring, and data becoming major bottlenecks. He says the company reached two to three thousand staff at one point. No cost breakdown is given, so margins cannot be reconstructed from the reported revenue figures. For an operator, capacity planning must include consumables, lab shifts, turnaround times, error handling, regulatory oversight, and backup suppliers. The business also had to manage a steep demand cliff; it released about 2,000 people when COVID testing fell away. Treat that decision as evidence that fixed capacity can become a liability quickly. Flexible staffing, modular capacity, and a deliberate wind-down plan belong in the original model, not as emergency afterthoughts.
Our read: copy the speed of identifying a bottleneck and packaging a complete service around it, but do not copy emergency-market assumptions. Prenetics had an existing life-sciences base and could use its laboratory capability when demand surged. A smaller founder can borrow the discipline of mapping the whole customer journey, from acquisition through delivery and result communication, then removing friction at each handoff. In a normal market, choose a recurring diagnostic or compliance workflow with durable demand and begin with an established lab partner rather than buying equipment. Secure a narrow customer segment, validate willingness to pay, and prove service quality before adding fixed capacity. Build contracts with explicit service levels, data safeguards, and contingency provisions. The defensible part is operational reliability and trust; low prices alone are not durable differentiation. Model a base case and a downside case in which demand falls sharply, and make sure leases, staffing, and inventory can flex with it.
The central risk is demand concentration in a temporary public-health emergency. Testing volumes collapsed when circumstances changed, leaving a company that had grown rapidly to resize its workforce and operations. Regulatory requirements, inaccurate results, supply disruption, and logistics failures could each damage trust and invite legal or public-sector consequences. Large contracts can concentrate revenue in a few buyers and require the provider to mobilize before payment or reimbursement. Rapid expansion also increases training and quality-control risk; a service that works at hundreds of tests a day may fail at tens of thousands without disciplined process design. Founder-reported revenue and profit figures are not independently verified in this entry. The model is a scale reference, not a plan for a new entrant to chase an emergency. Any adjacent opportunity needs durable, year-round use, compliant operations, diversified buyers, and an explicit capacity-reduction plan.
The four founder playbooks — first customers, first dollar, the flywheel, the silent stretch — are in the Unicorn Club, on this idea and on all 1,403 others. The story, the numbers, the sources and every later section stay open to everyone.
Join the Unicorn Club — $5/moCancel anytime, in one click